56 results about "Inflammatory bowel disease drug" patented technology

Isoalantolactone derivatives and their application in preparation of drugs for treating inflammatory bowel diseases are provided, and an isoalantolactone derivative shown as in formula (I) is provided; a salt-forming acid is an inorganic acid or organic acid, the inorganic acid is selected from hydrofluoric acid, hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, nitric acid, phosphoric acid, carbonic acid, bromic acid, seleninic acid, phosphomolybdic acid, phosphorus acid and sulfurous acid, and the organic acid is selected from citric acid, maleic acid, D-malic acid, L-malic acid, DL-malic acid, L-lactic acid, D-lactic acid, DL-acid, oxalic acid, methylsulfonic acid, pentanoic acid, oleic acid, lauric acid, p-methylbenzene sulfonic acid, 1-naphthalene sulfonic acid, 2-naphthalene sulfonic acid, phthalic acid, tartaric acid, malonic acid, succinic acid, fumaric acid, glycolic acid, mercapturic acid, glycine, creatine, sulfonic acid, nicotinic acid, picolimic acid, isonicotinic acid, and benzoic acid or substituted benzoic acid.

An application of chrysopolyose in preparing medicines to treat inflammatory enteropathy is disclosed. A process for preparing chrysopolyose includes such steps as pulverizing rhubarb, removing liposoluble component, refluxing extraction with distilled water, concentrating, deposition, decolouring, removing protein by the freeze-thaw method several times then by the sevag method several times. determining by stags saccharide content, dialysis, filtering, concentrating, freeze-drying and depositing by stages in absolute alcohol.

The invention relates to new application of schisandra chinensis total polysaccharide in preparation of medicines or health products for treating inflammatory bowel diseases, in particular to new application in preparation of medicines or health products for treating ulcerative colitis (UC), Crohn disease (CD) and acute and chronic intestinal diseases. Experiments show that the schisandra chinensis total polysaccharide can significantly improve inflammatory injury of colon, reduce spleen indexes, increase thymus indexes, effectively reduce the contents (activity) of MPO, NO, MDA and ROS in thecolons, and increase the contents of GSH and SOD at the same time. Meanwhile, the schisandra chinensis polysaccharide regulates the composition and diversity of intestinal microorganisms of colitis mice, obviously improves the relative abundance of Finnicutes, sugar bacteria, Enterorhabdus and the like, reduces the relative abundance of intestinal bacteria such as Firmicutes, Turicibacter and Akkermansia, remarkably increases the contents of propionic acid, butyric acid and isobutyric acid in the colon, and it is prompted that the schisandra chinensis total polysaccharide can be used for preparing medicines for treating or improving inflammatory bowel diseases.

The invention relates to the application of modified polysaccharide rich in galactose in medical preparation, in particular to application of modified polysaccharide rich in galactose in medicines for preventing and treating inflammatory bowel diseases. Aiming to fill the blank of preventing and treating inflammatory bowel disease by targeted gm-3-TLR4 access, the invention provides the technical scheme of the application of modified polysaccharide rich in galactose in treating inflammatory bowel disease, and the modified polysaccharide rich in galactose comprises natural gum or plant polysaccharide. The invention has the advantages that galectin-3 is used as the acting target, and the change of TLR4 in IBD is influenced through the regulation of the change of galectin-3, thereby promoting cell multiplication, inhibiting apoptosis and promoting injury repair. By adopting modified polysaccharide rich in galactose to treat colitis, the efficacy is good, high expression of galectin-3 can be induced, and the injury repair can be promoted; therefore, the side effect is small, and the modified polysaccharide rich in galactose can be used for a long term.

The present invention relates to an andrographolide enteric targeting micropellet and a method for preparation thereof; furthermore, the present invention also relates to uses of andrographolide and andrographolide enteric targeting micropellets in preparation of a pharmaceutical for treatment of inflammatory bowel disease.

The invention belongs to the technical field of traditional Chinese medicines, and relates to a novel pharmaceutical application of Houttuynia cordata Thunb. polysaccharide, in particular to the application of the Houttuynia cordata Thunb. polysaccharide in preparation of a medicine for preventing and treating inflammatory bowel disease (IBD). A total polysaccharide extract is separated and extracted from the traditional Chinese medicine Houttuynia cordata Thunb., the average product yield is 3.65%, and the polysaccharide content exceeds 70%. An integral experiment proves that the total polysaccharide extract of the Houttuynia cordata Thunb. has a remarkable treatment effect on mouse colonic injury induced by 2.5% DSS. The Houttuynia cordata Thunb. polysaccharide may inhibit infiltration of inflammatory cells, reduce secretion of inflammatory cytokines and inhibit expression of an inflammatory transcription factor NF [kappa] B through an anti-inflammatory mechanism of the Houttuynia cordata Thunb. polysaccharide, so that intestinal injury is reduced, intestinal mucosa is protected, and colon shortening and weight loss are relieved. The Houttuynia cordata Thunb. polysaccharide can be used for preparing medicines for preventing and treating ulcerative colitis.

The invention creatively provides an application of typhagoside in preparation of a medicine for treating inflammatory bowel diseases. According to the application disclosed by the invention, a DSS-induced C57BL/6J mouse colitis model is treated by the typhagoside. Inflammation-related parameters such as weight loss, disease activity index and spleen weight of a mouse are improved, histological staining reveals that intestinal inflammation of the mouse is inhibited, and the pathological score is reduced. By further investigating a specific mechanism of anti-inflammatory effect, the result shows that the typhagoside can inhibit activation of an NF-kB pathway in mouse intestinal epithelial cells and reduce expression of inflammatory factors in the mouse intestinal epithelial cells. In conclusion, the Chinese herbal monomer typhagoside can provide a new way for preparing medicines for treating IBD and related diseases thereof in the future.

The application of flagellin derivative CZLC31 from Salmonella in preparation of medicines for preventing and treating inflammatory bowel disease (IBD) is introduced in this invention. The CZLC331 protein has a good preventive and therapeutic effect for IBD, such as ulcerative colitis (UC) and Crohn's disease (CD) in this invention. Therefore, this protein can be prepared into the drug for prevention and treatment of IBD. It has been found that the bad efficacy, slow onset, long course of treatment, side effects can be significantly avoided for existing clinical IBD drugs, it can reduce the patient's pain during the treatment in this invention. The rehabilitation and quality of life of the patients have been largely improved. The drug will play an important role in the prevention and treatment of IBD in this invention, and has broad application prospects.

The invention discloses application of folium perillae extracts in preparation of a medicine for treating and/or preventing the inflammatory bowel disease. The folium perillae extracts disclosed by the invention have a reverse effect on diarrhea, hematochezia, weight loss and the colon position pathological injuries of a mouse with inflammatory bowel disease induced by low molecular weight dextransulfate, can obviously inhibit secretion of model mouse colon tissue cell factors NO, IFN-gamma, IL-4, IL-10 and IL-17, and can obviously inhibit the intestinal tissue MPO level of the model mouse.

The present invention relates to a therapeutic agent for inflammatory bowel disease comprising 5-chloro-6-(2-iminopyrrolidin-1-yl)methyl-2,4(1H,3H)-pyrimidinedione or a pharmaceutically acceptable salt thereof as an active ingredient.

According to the present invention, an effective and safe therapeutic agent for inflammatory bowel disease including ulcerative colitis and Crohn's disease can be provided. The balance between the therapeutic effect on a chronic inflammation such as inflammatory bowel disease and the adverse side effect of the compound is superior to those of an aminosalicylic acid preparation and a corticosteroid preparation, which cannot be expected at all from a mere anti-diarrheal effect.

The invention provides application of an MG53/MG53 mutant-containing composition in preparation of a drug for preventing and treating the inflammatory bowel disease. The mutant is non-polar amino acidalanine mutated from a serine site in the Coiled-coil structural domain of MG53. A mouse ulcerative colitis model is built through induction of dextran sulfate sodium (DSS); 5-aminosalicylic acid (5-ASA) is used as a positive drug for contrast; evaluation of a disease activity index (DAI), the length of a colon, a weight change and pathological changes of a colon tissue verifies that the composition has an obvious inhibition effect on the DSS-induced colitis.

The invention discloses an application of decitabine in the preparation of a medicine for treating inflammatory bowel diseases. The decitabine can improve the proportion of spleen regulatory T cells of mice with inflammatory bowel diseases. The content of regulatory T cell related cytokines in colon tissues of mice with inflammatory bowel diseases can be increased; the expression of tight junctionprotein of colon tissues of mice with inflammatory bowel diseases can be improved; and colon lesions of inflammatory bowel diseases of mice can be obviously controlled. Decitabine can induce immune tolerance of inflammatory bowel disease patients to intestinal non-pathogenic antigens, recover intestinal barrier functions, improve effective rate and alleviation rate, and reduce recurrence rate.

The invention discloses an application of a pueraria flower extract in preparation of drugs for preventing, treating and relieving inflammatory bowel diseases, protecting intestinal barriers and stabilizing intestinal morphology, provides a reliable anti-inflammatory agent to help to maintain the balance of the intestinal environment, and has the advantages of good curative effect on the inflammatory bowel diseases, low price and no obvious side effect. The invention finds and verifies that the pueraria flower extract has a remarkable curative effect on inflammatory bowel diseases, is low in price and side effect, and can macroscopically improve the intestinal inflammation state by improving the body health level, reducing the intestinal permeability, prolonging the intestinal length and the like. The pueraria flower extract can relieve excessive proliferation and differentiation of precursor cells caused by exogenous proinflammatory factors by negatively regulating an important factor, namely a JAK-STAT signal channel, of a colitis pathogenesis and maintain the homeostasis of intestinal cells, so that the effect of treating the inflammatory bowel disease is achieved.

The invention provides applications of a ROCK2 inhibitor in preparing medicines for treating inflammatory bowel diseases. By discovering the effects of the ROCK2 activity level in the intestinal inflammation, the invention provides applications of a ROCK2 activity selective inhibitor SLx-2119 in preparing medicines for treating inflammatory bowel diseases.

The invention discloses an application of a kaurane compound in preparation of a medicine for treating inflammatory bowel disease. The kaurane compound can obviously reduce the weight of a dextran sodium sulfate induced (DSS) enteritis model mouse, improve the shortening of the colon length of the colitis model mouse, relieve the infiltration of colon tissue inflammatory cells of the colitis model mouse, reduce the rise of leukocytes, neutrophils, lymphocytes and monocytes of the colitis model mouse, reduce the expression of inflammatory factors, and achieve the immunoregulation function on intestinal tracts. The mechanism of the kaurane compound may be known by adjusting polarization of macrophages and differentiation of T cells, and the kaurane compound can relieve the inflammatory reaction of DSS-induced inflammatory bowel disease model mice and improve the severity of the inflammatory bowel disease, and can be used for preparing drugs or health care products for treating the inflammatory bowel disease.

The invention provides application of Alistipes putredinis bacteria in preparation of a medicine for preventing and treating inflammatory bowel diseases, and relates to the technical field of biological medicines. A C57BL/6 mouse colitis model is adopted, and it is found that the A.putredinis bacterium can improve intestinal inflammation of DSS mice. It is confirmed for the first time that A.putredinis can inhibit intestinal inflammation of mice with DSS colitis, a new theory is provided for pathogenesis of CD, a new treatment strategy is provided for CD diagnosis and treatment, and potential clinical application prospects are achieved.

The invention discloses an application of phosphatidylserine in preparation of medicines for treating inflammatory bowel diseases, and the medicines taking effect of the phosphatidylserine in inflammatory bowel diseases as a target. In the inflammatory bowel diseases, the phosphatidylserine of vascular endothelial cells is exposed to an extracellular membrane from an intracellular membrane. The exposed phosphatidylserine can be used as a marker for the inflammatory bowel diseases and can be used for screening medicines for treating the inflammatory bowel diseases. According to the invention, Annexin A5 is determined to have a remarkable curative effect in treatment of the inflammatory bowel diseases. The Annexin A5 is found to be specifically combined with capillaries enriched in intestinal mucosa through PS and to inhibit adhesion and infiltration of inflammatory cells to achieve the anti-inflammatory effect for the first time.

The invention provides streptococcus salivarius and an application thereof to preparation of medicines for treatment of inflammatory bowel diseases, and relates to the field of a biological technology. The streptococcus salivarius (streptococcus salivarius) 1802 is preserved in the preservation center with the preservation number of CCTCC NO:M 2019251. A screening method of the streptococcus salivarius comprises the steps of enabling excrement of healthy people to be subjected to suspension with bacteria-free water, performing diluting until the volume is 10-6 times, and performing fractionalcultivation in a brain-heart leaching solution culture medium with a plate streak to obtain the streptococcus salivarius (streptococcus salivarius) 1802. The streptococcus salivarius (streptococcus salivarius) 1802 can be applied to preparation of medicines for treatment of inflammatory bowel diseases, can be used in medicines for relieving inflammatory reactions of the inflammatory bowel diseases, and can be applied to medicines for relieving inflammatory bowel disease colon mucous membrane injury.

The invention discloses new application of total alkaloids in melodinus khasianus, that is, application of a medicine for preventing or/and treating an inflammatory bowel disease, and belongs to the technical field of development of natural drugs or medicines. According to the application of the total alkaloids in the melodinus khasianus disclosed by the invention, by using aerial parts of the melodinus khasianus as raw materials, the total alkaloids in the melodinus khasianus are obtained through ultrasonically extracting methanol water and performing acid-alkali treatment; the plants of themelodinus khasianus are widely distributed and are low in cost, and raw materials are easy to get, and therefore, an extraction process of the alkaloids is simple. According to the application of thetotal alkaloids in the melodinus khasianus disclosed by the invention, a colonitis model is built through DSS-induced C57BL/6 mice, and by adopting the total alkaloids in the melodinus khasianus, expression of related inflammatory factors in DSS-induced colon tissues can be effectively inhibited, the activity of related oxydase in the colon tissues can be improved, and the total alkaloids in the melodinus khasianus have certain prevention and treatment effects on the inflammatory bowel disease and have good development and application prospects in preparation of the medicine for preventing or/and treating the inflammatory bowel disease.

The invention discloses application of sodium p-hydroxybenzoate in preparation of a medicine for treating or preventing inflammatory bowel diseases. Under the condition that the dosage is obviously lower than that of mesalazine, sodium p-hydroxybenzoate can obviously inhibit the increase of the disease activity index score of enteritis model mice induced by dextran sodium sulfate, improve the contraction in length of colons of colitis model mice, reduce the MPO activity of the colons of the mice, and relieve inflammatory cell infiltration of colons of the colitis model. The invention also discloses a medicine for treating or preventing inflammatory bowel diseases. Sodium p-hydroxybenzoate is used as an effective component of the medicine and the medicine contains an effective dose of sodium p-hydroxybenzoate in treatment.